MYUNGMOON Pharm co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 2,209.14 million compared to KRW 2,007.59 million a year ago. Net income was KRW 93.93 million compared to net loss of KRW 133.82 million a year ago. Basic earnings per share from continuing operations was KRW 3 compared to basic loss per share from continuing operations of KRW 4 a year ago. Basic earnings per share was KRW 3 compared to basic loss per share of KRW 4 a year ago.
For the nine months, sales was KRW 6,372.39 million compared to KRW 5,324.23 million a year ago. Net income was KRW 3,235.24 million compared to KRW 1,140.73 million a year ago. Basic earnings per share from continuing operations was KRW 96 compared to KRW 34 a year ago. Basic earnings per share was KRW 96 compared to KRW 34 a year ago.